Seeking Alpha
16 Jul 2026, 09:44 UTC · 2h ago
Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
16 Jul 2026, 09:44 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
AMVUTTRA is projected to generate $890 million in revenue by Q1 2026. — Specific, high-growth revenue targets for a core product are primary drivers of valuation and stock price.
+0.80AMVUTTRA currently maintains a near-term commercial monopoly in TTR silencing. — Monopoly positioning allows for significant pricing power and accelerated market share capture.
+0.70Alnylam has achieved GAAP profitability and maintains a $3.0 billion cash position. — Profitability and strong liquidity significantly lower the bankruptcy risk and funding needs typical of biotech firms.
+0.50Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The analyst initiates coverage with a BUY rating, highlighting a commercial monopoly, strong revenue projections, and GAAP profitability.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
1h ago
